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ABSTRACT
Background. The use of routine CT imaging for surveil-
lance in asymptomatic patients with cutaneous melanoma
is controversial. We report our experience using a
surveillance strategy that included CT imaging for a cohort
of patients with high-risk melanoma.
Methods. A total of 466 patients with high-risk cutaneous
melanoma enrolled in adjuvant immunotherapy trials were
followed for tumor progression by physical examination,
labs, and CT imaging as defined by protocol. Evaluations
were obtained at least every 6 months for year 1, every 6
months for year 2, and then annually for the remainder of the
5-year study. Time to tumor progression, sites of recurrence,
and the method of relapse detection were identified.
Results. The patient cohort consisted of 115 stage II
patients, 328 stage III patients, and 23 patients with
resected stage IV melanoma. The medium time to pro-
gression for the 225 patients who developed tumor
progression was 7 months. Tumor progression was detected
by patients, physician examination or routine labs, or by
CT imaging alone in 27, 14, and 59% of cases respectively.
Melanoma recurrences were noted to be locoregional in
36% of cases and systemic in 64% of cases. Thirty percent
of patients with locoregional relapse and 75% of patients
with systemic relapse were detected solely by CT imaging.
Conclusions. CT imaging alone detected the majority of
sites of disease progression in our patients with high-risk
cutaneous melanoma. This disease was not heralded by
symptoms, physical examination, or blood work. Although
the benefit of the early detection of advanced melanoma is
unknown, this experience is relevant because of the rapid
development and availability of potentially curative
immunotherapies.
Although the risk for relapse for patients with stage II, III,
and resected stage IV cutaneous melanoma is recognized to
be high, optimal follow-up surveillance strategies remain
controversial. The wide variation in surveillance practice
patterns is unfortunate but understandable given the lack of
level 1 evidence, conflicting retrospective data, and the
significant cost associated with aggressive follow-up. The
National Comprehensive Cancer Network (NCCN) follow-
up guidelines for stage IIB or greater melanoma recommend
physical examination every 3 to 6 months with chest x-ray
and serum LDH and to consider annual computed tomog-
raphy (CT) scans.1 This report describes the results of our
experience utilizing an aggressive surveillance strategy that
was strictly defined and implemented as a component of
adjuvant immunotherapy protocols conducted for patients
with melanoma at the Surgery Branch, NCI.
METHODS
Patient Selection
A retrospective analysis was performed using patients
enrolled in one of four different institutional review board-
approved adjuvant immunotherapy trials conducted in the
Surgery Branch, National Cancer Institute between 1998
and 2009. The inclusion criteria for these four studies were
identical and included patients with stage II, stage III, and
resected stage IV cutaneous melanoma. Patients with
ulcerated or C1.5-mm primary melanomas, completely
resected local regional nodal disease, or completely
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resected metastatic disease were eligible if HLA appro-
priate and enrolled within 6 months of surgery. These trials
were designed using the 5th edition of the AJCC staging for
cutaneous melanoma as recognized in 1998. Staging was
modified to include tumor ulceration.2,3 Patients with
ocular or mucosal melanoma or who required steroids were
excluded. Eligible patients were screened with physical
exam, lab tests, brain MRI, and CT scan of chest, abdomen,
and pelvis. Following adjuvant immunotherapy, patients
were monitored closely for recurrence by physical exami-
nation, labs, and imaging as required by protocol for 5
years. Patient follow-up was censored for disease pro-
gression or discharge from clinic at year 5. Some patients
elected to continue annual surveillance at the Surgery
Branch off protocol beyond 5 years, although data gener-
ated beyond 5 years was not included in this report.
Protocols and Surveillance Strategy
The Surgery Branch, NCI conducted three successive
pilot adjuvant immunotherapy protocols to evaluate peptide
immunization to a variety of melanocyte differentiation
antigens, including gp 100, MART-1, and tyrosinase. The
fourth protocol was a cellular vaccine consisting of periph-
eral blood lymphocytes transduced with a T-cell receptor
(TCR) that recognized the HLA-A*02-restricted MART-1
antigen. Details of these studies can be found by using the
Clinical trials.gov identifier noted in Table 1. All protocols
required CT imaging of chest, abdomen, and pelvis and MRI
brain imaging within 4 weeks of protocol enrollment. Sub-
sequent brain imaging was obtained if neurologic symptoms
were detected or as part of a metastatic survey following
disease progression at other sites. Because each protocol had
a different vaccination schema, there were minor variations
in surveillance schedules during year 1. However, all
patients had complete clinical evaluations and CT imaging
within 4 weeks of protocol enrollment and at least two more
times during the first year of the study. Subsequent clinical
and imaging evaluations were very similar for all four of the
clinical trials. The protocol surveillance schedules are
described below and outline in Table 2. The results of these
pilot studies have been published in part.4–6
RECURRENCE CLASSIFICATION
Patients documented to have progressive melanoma
were analyzed for demographic information, time and site
of first recurrence, and the method of detection of tumor
progression (patient detection, physician examination/lab
TABLE 1 Clinical and pathological characteristics of patients with

















00C0216 (Tyr 240-251/IF or gp100 204 (44)
03C0172 (MART 1:27-35) 113 (24)
06C0069 (gp100:209-217M/montar) 101 (22)
















Every 3 months Every 3 months Every 6 months Yearly
NCT 00059475
(N = 113)
Every 3 months Every 6 months Every 6 months Yearly
NCT 00273910
(N = 101)
Every 3 and 9 months Every 3 and 9 months Every 6 monthsa Yearly
NCT 00706992
(N = 48)
Every 3, 6, 12 months Every 3, 6, 12 months Every 6 months Every 6 months
a A small subset of this cohort elected to start annual surveillance at 18 months
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abnormality, or CT imaging). For CT imaging to have been
considered the method that detected disease progression,
patients were required to be asymptomatic and to have
normal labs and physical examination. For physician
examination/lab abnormality to have been considered the
method of detection, patients also were required to be
asymptomatic. Finally, patients who presented with
symptoms or new findings detected by the patient were
categorized as patient-detected. For this group, no dis-
tinction was made between patients who had tumor
recurrence identified at a regularly scheduled follow-up
visit and those who an evaluation for symptoms more
urgently at an unscheduled appointment.
Locoregional relapse was defined as the identification
new local/intransit or regional nodal. Systemic relapse
included identification of intrathoracic, bone, intra-ab-
dominal and CNS, as well as cutaneous/muscle/nodal
recurrences, which were distant from the primary site.7
Patients who relapsed at several sites concomitantly were
scored on the basis of the site that was most advanced.
RESULTS
Patient Demographics and Relapse Incidence
A total of 466 patients enrolled on an adjuvant
immunotherapy trials were identified and evaluated. Of
these, 115 (25%) had resected stage II disease, 328 (70%)
had stage III, and 23 (5%) had stage IV disease. Sixty-three
percent of patients were male, and 37% were female. The
median patient age was 49 years. The majority of patients
had a primary located on an extremity (41%), 36% had a
primary located on the trunk, 15% had a head or neck
primary, and 8% had a primary of unknown origin
(Table 1).
Of the 466 patients, 225 (48%) developed disease pro-
gression during the 5-year observation period. For these
patients, the median time from protocol enrollment to the
date of identified tumor progression was 7 months. There
were no differences in the rates or timing of relapses
between the four adjuvant trials. Approximately 94% of
relapses were detected by 3 years and 99% of relapses were
noted by 4 years. Not surprisingly, stage IV patients were
more likely to demonstrate early disease progression
(Fig. 1).
Site of First Relapse
Table 3 documents the sites of disease progression as
either local regional or systemic using the previously
defined criteria for the 225 patients who developed relapse.
The first relapse among stage II patients was locoregional
in 52% of patients and systemic in 48% of patients. Among
those with stage III disease, the site of tumor progression
was locoregional in 32% of patients and systemic in 68%
of patients. For patients with resected stage IV disease at
protocol enrollment and who demonstrated tumor pro-
gression, the disease was identified as locoregional in 23%
of patients and systemic in 77% of patients.
Method of Detection
The method by which disease progression was first
detected was classified as by patient, by physician or lab
analysis, or by CT imaging alone (Table 4). For the 225
individuals who recurred, 60 were detected by the patient
(27%), 32 by physicians or labs (14%), and 131 by CT
imaging alone (59%). For the 81 patients with local
regional recurrence, 36 (45%) recurrences were patient-
detected, 20 (25%) were detected by physician
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FIG. 1 Kinetics of melanoma progression by stage. Relapse-free
survival of all 225 patients with melanomas stage II, III, IV who
relapsed
TABLE 3 Site of first recurrence
Stage Total patients Total recurrence Locoregional Systemic
Stage II 115 54 28 (52%) 26(48%)
Stage III 328 158 50 (32%) 108 (68%)
Stage IV 23 13 3 (23%) 10 (77%)
Total 466 225 81 (36%) 144 (64%)
Locoregional is defined as local, in-transit, and nodal metastases
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examination, and 24 (30%) were identified by imaging
alone. Not surprisingly, patients and physicians were more
likely to diagnose locoregional disease and less likely to
detect progressive systemic disease.
As expected, CT imaging was the most effective method
to detect systemic progression of melanoma. For the 144
patients who developed systemic recurrence, 107 (75%)
were detected by imaging in an asymptomatic patient with
normal labs and physical examination. Twenty-four (17%)
recurrences were patient-detected. These individuals noted
a new tumor and had concomitant metastatic disease
detected or complained of pain, bleeding, or neurologic
symptoms. Nine patients had their systemic disease
detected by physician examination, and only three patients
had abnormal laboratory finding which suggested disease
progression. These individuals developed anemia from
intestinal metastasis and are included in the physician-de-
tected cohort. As noted in Table 4, two patients had
metastatic disease detected by physical examination, but
the medical record was unclear if this was by the patient’s
or physician’s examination. Both of these patients were in
the resected Stage IV cohort; one recurred with locore-
gional disease and one with systemic disease.
Serum LDH was routinely obtained at each follow-up
evaluation. LDH elevation was recorded at least once in
13% of patients who remained free of disease during the
observation period and in only 3.5% of patients at the time
tumor progression was detected in patients with tumor
progression. Neither LDH nor LFTs appeared to be useful
for surveillance.
Detection of Brain Metastasis
Melanoma brain metastases were detected in 17 (4%) of
466 evaluable patients and in 7.5% of the 225 patients who
developed progressive melanoma during surveillance.
Given our brain surveillance strategy, it is not surprising
that 14 of these patients presented with neurologic symp-
toms, including headache, visual changes, or seizures. The
remaining three patients had brain disease identified as part
of a complete metastatic survey that was initiated, because
progression had been detected at other sites. Interestingly,
11 of the 17 patients with brain metastasis patients had
brain-only disease. Sixteen of the 17 patients had stage III
or resected stage IV disease at protocol entry.
DISCUSSION
This report describes the results of a surveillance strat-
egy for patients with stage II, III, and resected stage IV
cutaneous melanoma that was implemented for adjuvant
immunotherapy trials conducted at the Surgery Branch,
NCI, and that included the routine use of CT imaging.
Although there was some variation in the timing of eval-
uations during the first year for each protocol, surveillance
for all patients included imaging of the chest abdomen and
pelvis at intervals of 6 months or less for year 1, every 6
months for year 2, and then annually through year 5 and
protocol termination. We found that CT imaging identified
a large number of cases of progressive melanoma that were
missed by both patients and physicians. This was evident
whether the site of disease progression was systemic or
locoregional. This also was the case for our patients
regardless of their stage at time of protocol enrollment.
Current NCCN guidelines for surveillance of patients
with high-risk melanoma consider routine cross-sectional
imaging to be optional. Reports that have addressed this
issue generally have used CT imaging to evaluate patient
symptoms or physical findings.8–13 One notable exception
is the report by Romero et al. from Memorial Sloan-Ket-
tering Cancer Center.7 In this retrospective series, patients
with stage III melanoma were evaluated every 3 months for
2 years and subsequently every 6 months. Although the
imaging frequency was not specified, CT images were said
TABLE 4 Method of detection by site and stage
Total recurrences Patient detecteda Physician detecteda Imaging detected
225 60 (27%) 32 (14%) 131 (59%)
By site
Locoregional—81 36 (45%) 20 (25%) 24 (30%)
Systemic—144 24 (17%) 12 (8%) 107 (75%)
By stage
II—54 18 (33%) 6 (11%) 30 (56%)
III—158 37 (23%) 26 (17%) 95 (60%)
IV—13 5 (38%) 0 6 (46%)
a Two patients were detected by physical exam but it was unclear whether by patient or physician exam
Pt 1 presented as stage 4, recurred systemically; Pt 2 presented as stage 4, recurred locoregionally
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to be obtained typically before each evaluation. These
authors noted that 53% of tumor relapses were detected
only by CT imaging. A fact that also was consistent with
our findings was that serum LDH and LFTs were not
helpful when screening patients at risk for melanoma
recurrence. However, in our series we did detect gas-
trointestinal metastasis as an initial site of disease
progression in three patients following an evaluation per-
formed solely to evaluate asymptomatic anemia.
Our experience confirms that a surveillance strategy for
asymptomatic patients with high-risk cutaneous melanoma
should include routine cross-sectional imaging. CT
surveillance identified a large number of locoregional
relapses missed by patients and physicians as well as
unsuspected systemic disease. Of the 225 patients who
recurred during the 5-year observation period, 13 (6%)
developed tumor progression after year 3. Although NCCN
guidelines do not recommend imaging beyond 3 years, 11
of these 13 patients had disease progression detected by
imaging alone. Our future adjuvant immunotherapy pro-
tocols will include CT imaging every 6 months for the first
2 years followed by annual imaging. Blood work will
include a CBC. Obviously, our report does not help to
clarify surveillance techniques beyond 5 years. Finally,
PET imaging was obtained on only 16 patients in this
series. Consequently, our experience does not address the
role of PET in surveillance strategies for patients at high
risk for developing progressive melanoma.
We recognize that surveillance for patients at risk for
melanoma relapse has not been documented to improve
overall survival. However, the recent approval of adjuvant
ipilimumab obviously has changed the therapeutic landscape
for these patients and highlights the need for effective
surveillance.14 The development of multiple and potentially
curative immunotherapies, including high-dose interleukin-
2, check point inhibitors, and ACT, make the timely identi-
fication of metastatic melanoma a high priority.15–21
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